Aleniglipron Hepatic Impairment Study

StatusNot Yet Recruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
The purpose of this study is to evaluate the PK of aleniglipron in participants with Hepatic Impairment to establish scientifically guided dosing recommendations in these special patient populations.
Trial Details
NCT Number NCT07872033
Lead Sponsor Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Conditions
(from sponsor)		 Hepatic Impairment
Enrollment 36 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov